![Mirixa2019](http://www.firstanalysis.com/webfiles/PR/Mirixa/Mirixa2019.png)
CHICAGO – January 10, 2019 – First Analysis acted as the exclusive financial advisor in the sale of Mirixa, a leading healthcare technology and services company specializing in medication therapy management (MTM). First Analysis provided advisory expertise to Mirixa throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
The purchase was made by Cardinal Health Inc. This purchase will enable the combined company to grow market share, accelerate product development and expand services and support for existing and new clients.
“From the first meeting, it was clear that First Analysis’s in-depth knowledge of the healthcare technology space would be invaluable in helping to maximize our return,” said Frank Harvey, CEO of Mirixa. “Every member of the team surpassed our expectations and were instrumental in not only identifying the appropriate target acquirers but also in helping to work through road blocks that emerged during the deal process.”
Headquartered in Reston, VA, Mirixa is the leading provider of medication therapy management software solutions. The Company’s solution and large pharmacy footprint enable its customers to successfully engage patients, manage chronic conditions, and improve adherence and clinical outcomes while reducing healthcare costs.
About First Analysis
Founded in 1981, First Analysis has a 38-year track record of serving emerging growth companies and established industry leaders within its focused areas of domain expertise. Our investment banking practice leverages industry insights developed through our equity research and private equity activities to deliver value to clients across the life cycle of a business. Providing senior-level attention to every client, First Analysis offers superior execution across a comprehensive range of investment banking services, including M&A advisory, public equity and debt financing, and private equity placements.
For additional information about how the investment banking professionals at First Analysis Securities Corporation can help you, please visit our website, www.firstanalysis.com, or call us at (312) 258-1400.
Brian Friedman
Managing Director
312-258-7110
bfriedman@firstanalysis.com
To download a pdf version of this press release, please follow the link below:
First Analysis acted as the Exclusive Financial Advisor to Mirixa in its sale to Cardinal Health
First Analysis Securities Corp. (FASC) is a registered broker/dealer with FINRA and member SIPC.